Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sainio, M.
Right arrow Articles by Jaaskelainen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sainio, M.
Right arrow Articles by Jaaskelainen, J.

Neurology, Vol 45, Issue 7 1314-1322, Copyright © 1995 by American Academy of Neurology

ARTICLES

Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree

M Sainio, T Strachan, G Blomstedt, O Salonen, K Setala, A Palotie, J Palo, I Pyykko, L Peltonen and J Jaaskelainen
Department of Neurology, University of Helsinki, Finland.

Neurofibromatosis 2 (NF2), a dominantly inherited disorder, typically manifests as bilateral vestibular schwannomas and predisposes to other nervous system tumors. In this study, we present a large pedigree with a benign course of NF2 (mild Gardner type) characterized by slowly growing vestibular schwannomas but few other manifestations. The family was thoroughly investigated with neurologic, ophthalmologic, and neuro- otologic methods including gadolinium-enhanced MRI of the head and spine and DNA linkage analysis. In the clinical analysis of 22 family members, MRI was superior to neuro-otologic methods in the detection of asymptomatic tumors. Based on the DNA linkage analyses we identified the NF2 mutation carriers with a high degree of certainty. These DNA markers (CRYB2, NEFH, D22S268, and D22S280) can also be used for presymptomatic diagnosis in other NF2 families. Early detection of NF2 gene mutation carriers has become possible using linkage analysis in familial NF2. MRI screening of carriers will reveal presymptomatic vestibular schwannomas (and other CNS tumors), making early intervention possible, but an efficient treatment strategy to prevent deafness has not yet been established.


This article has been cited by other articles:


Home page
 J. Med. Genet.Home page
M E Baser, L Kuramoto, R Woods, H Joe, J M Friedman, A J Wallace, R T Ramsden, S Olschwang, E Bijlsma, M Kalamarides, et al.
The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2
J. Med. Genet., July 1, 2005; 42(7): 540 - 546.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Sainio, J. Jaaskelainen, H. Pihlaja, and O. Carpen
Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus
Neurology, March 14, 2000; 54(5): 1132 - 1138.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Antinheimo, R. Sankila, O. Carpen, E. Pukkala, M. Sainio, and J. Jaaskelainen
Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas
Neurology, January 11, 2000; 54(1): 71 - 71.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.